HTBX - ヒ―ト・バイオロジクス （Heat Biologics Inc.）HTBXのニュース
Heat Biologics stock soars 9% on supply contract with Canada for anthrax drug Anthim 2022/04/27 12:51:42 Seeking Alpha
Heat Biologics (HTBX) said its unit Elusys Therapeutics finalized a contract with the Canadian government to deliver anthrax therapy Anthim
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM to the Canadian Government 2022/04/27 12:00:00 Wallstreet:Online
New contract marks the first international sale of ANTHIM and follows recent acquisition of Elusys by NightHawk DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders
Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics 2022/04/20 12:00:00 Benzinga
Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk acquired all outstanding shares of Elusys, which will continue to operate as a wholly-owned subsidiary of NightHawk. No stock or warrants were issued in connection with the acquisition, and Elusys had no outstanding term debt. The strategic acquisition of Elusys significantly expands the Company''s role in the biodefense space, complementing NightHawk''s RapidVax® platform, which is designed to target emerging biological threats.
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics 2022/04/20 12:00:00 Heat Biologics
Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient''s immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces…
Heat Biologics to rebrand as NightHawk Biosciences from next month 2022/04/19 15:49:33 Seeking Alpha
The clinical-stage biotech, Heat Biologics (HTBX), announced on Tuesday that it would change its name to NightHawk Biosciences effective May 03
Heat Biologics stock soars 9% on supply contract with Canada for anthrax drug Anthim 2022/04/27 12:51:42 Seeking Alpha
Heat Biologics (HTBX) said its unit Elusys Therapeutics finalized a contract with the Canadian government to deliver anthrax therapy Anthim
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM to the Canadian Government 2022/04/27 12:00:00 Wallstreet:Online
New contract marks the first international sale of ANTHIM and follows recent acquisition of Elusys by NightHawk DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders
Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics 2022/04/20 12:00:00 Benzinga
Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk acquired all outstanding shares of Elusys, which will continue to operate as a wholly-owned subsidiary of NightHawk. No stock or warrants were issued in connection with the acquisition, and Elusys had no outstanding term debt. The strategic acquisition of Elusys significantly expands the Company''s role in the biodefense space, complementing NightHawk''s RapidVax® platform, which is designed to target emerging biological threats.
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics 2022/04/20 12:00:00 Heat Biologics
Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient''s immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces…
Heat Biologics to rebrand as NightHawk Biosciences from next month 2022/04/19 15:49:33 Seeking Alpha
The clinical-stage biotech, Heat Biologics (HTBX), announced on Tuesday that it would change its name to NightHawk Biosciences effective May 03
Traders cant mares this Stock: Ford Motor Company (NYSE:F), Heat Biologics, Inc. (NASDAQ:HTBX) 2021/07/08 02:19:56 Stock Equity
Ford Motor Company (NYSE:F) with the stream of -1.17% also noticed, India Heat Biologics, Inc. (NASDAQ:HTBX) encountered a rapid change of -3.24% in the last hour of Wednesdays trading session. The post Traders cant mares this Stock: Ford Motor Company (NYSE:F), Heat Biologics, Inc. (NASDAQ:HTBX) appeared first on Stocks Equity .
Traders should take notice on: CommScope Holding Company, Inc. (NASDAQ:COMM), Heat Biologics, Inc. (NASDAQ:HTBX) 2021/06/28 23:32:34 Stock Equity
CommScope Holding Company, Inc. (NASDAQ:COMM) with the stream of -0.42% also noticed, India Heat Biologics, Inc. (NASDAQ:HTBX) encountered a rapid change of -1.52% in the last hour of MONDAYs trading The post Traders should take notice on: CommScope Holding Company, Inc. (NASDAQ:COMM), Heat Biologics, Inc. (NASDAQ:HTBX) appeared first on Stocks Equity .
Heat Biologics Joins Russell Microcap Index 2021/06/28 11:30:00 Wallstreet:Online
DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has been added to the Russell Microcap Index, following the annual Russell indexes reconstitution, effective after the US market opens today, June 28, 2021, according